These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 121852)
1. [Inflammatory tuberculoid leprosy and borderline leprosy treated with long-acting sulfamides (fanasil). Clinical, bacteriologic and immunologic changes in vivo and in vitro followed for 18 to 36 months]. Saint-André P; Ferraci C; Baquillon G; Travi Piacentile M Acta Leprol; 1979; (76-77):315-7. PubMed ID: 121852 [No Abstract] [Full Text] [Related]
2. Electrophysiological evidence for motor unit impairment during the treatment of leprosy. Linois H; Sebille A J Neurol Sci; 1980 Feb; 45(1):57-63. PubMed ID: 7359167 [TBL] [Abstract][Full Text] [Related]
3. [In vitro immunologic changes in 6 lepromatous leprosy or borderline leprosy patients treated with BCG alone or BCG and lepromin for 12 to 20 months, followed by BCG and antibiochemotherapy for 1 to 2 years]. Saint-André P; Ferracci C; Baquillon G; Travi Piacentile M Acta Leprol; 1979; (76-77):311-4. PubMed ID: 121851 [No Abstract] [Full Text] [Related]
4. A trial of long-acting sulphonamide R.O. 4-4393 (fanasil) in treatment of cases of lepromatous leprosy with repeated E.N.L. Ekambaram V; Venkatachari S Lepr India; 1976 Jan; 48(1):24-30. PubMed ID: 1022953 [TBL] [Abstract][Full Text] [Related]
5. [In vitro immunologic changes in 7 patients with lepromatous leprosy and borderline leprosy treated with levamisole]. Saint-André P; Travi Piacentile M; Baquillon G; Ferracci C Acta Leprol; 1979; (76-77):295-300. PubMed ID: 121848 [No Abstract] [Full Text] [Related]
6. [Resistance to disulone and sulfamides in Senegal (early experience with 39 cases--ILAD 1978-1980)]. Carayon A; Van Droogenbroeck J; Languillon J Acta Leprol; 1985; 3(4):317-27. PubMed ID: 3913268 [No Abstract] [Full Text] [Related]
7. Relation between anti-Mycobacterium leprae antibody activity and clinical features in borderline tuberculoid (BT) leprosy. Touw Langendijk EJ; van Diepen TW; Harboe M; Belehu A Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):305-11. PubMed ID: 6358061 [TBL] [Abstract][Full Text] [Related]
8. Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction. Moura DF; Teles RM; Ribeiro-Carvalho MM; Teles RB; Santos IM; Ferreira H; Fulco TO; Nery JA; Sampaio EP; Sarno EN Br J Dermatol; 2007 Aug; 157(2):273-83. PubMed ID: 17553031 [TBL] [Abstract][Full Text] [Related]
9. Mefloquine sulfadoxine pyrimethamine (MSP) combination delays in vitro emergence of mefloquine resistance in multiple drug resistant Plasmodium falciparum. Brockelman CR; Thanomsub B; Bhisutthibhand J Southeast Asian J Trop Med Public Health; 1989 Sep; 20(3):371-8. PubMed ID: 2699083 [TBL] [Abstract][Full Text] [Related]
10. [In vitro immunologic changes in 4 patients with lepromatous leprosy and 4 patients with borderline leprosy treated with Neisseria perflava for 17 to 25 months]. Saint-André P; Ferracci C; Travi Piacentile M; Baquillon G Acta Leprol; 1979; (76-77):291-3. PubMed ID: 121847 [No Abstract] [Full Text] [Related]
11. [In vivo resistance of Plasmodium falciparum to the combination of sulfadoxine and pyrimethamine, at RIII level, in Amazonas, Brazil]. Alecrim WD; Dourado H; Alecrim M das G; Passos LF; Wanssa E; Albuquerque B Rev Inst Med Trop Sao Paulo; 1982; 24(6 Suppl):52-3. PubMed ID: 6764290 [No Abstract] [Full Text] [Related]
12. [In vivo resistance of Plasmodium falciparum to 4-aminoquinolines and to a sulfadoxine-pyrimethamine combination. II. Study of Manaus, Amazonas 1983-1984]. Reyes S; Osanai CH; Passos AD Rev Bras Malariol Doencas Trop; 1986; 38():37-44. PubMed ID: 3077193 [No Abstract] [Full Text] [Related]
13. Effect of treatment on antibody activity against Mycobacterium leprae antigen 7 in tuberculoid leprosy. Dahle JS; van Diepen TW; Touw Langendijk EJ; Harboe M; Belehu A Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):312-20. PubMed ID: 6358062 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of recurrent congenital ocular toxoplasmosis. Our initial experience with Fansidar]. Comte P; Verin P; Le Bras M Bull Soc Ophtalmol Fr; 1989 Apr; 89(4):567-8, 571-2. PubMed ID: 2686844 [TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy. Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953 [TBL] [Abstract][Full Text] [Related]
16. The significance of changes in the nasal mucosa in indeterminate, tuberculoid and borderline leprosy. Chacko CJ; Bhanu T; Victor V; Alexander R; Taylor PM; Job CK Lepr India; 1979 Jan; 51(1):8-22. PubMed ID: 376945 [TBL] [Abstract][Full Text] [Related]
17. Inside the skin: the local immune and inflammatory milieu in leprosy. Scollard DM Am J Trop Med Hyg; 1991 Apr; 44(4 Pt 2):17-23. PubMed ID: 2042708 [TBL] [Abstract][Full Text] [Related]
18. [Unsuccessful effect of sulfadoxine-pyrimethamine in the treatment of falciparum malaria in Tanzania]. Vestergaard Olsen V Ugeskr Laeger; 1983 Mar; 145(10):751. PubMed ID: 6344376 [No Abstract] [Full Text] [Related]
19. [Resistance of Plasmodium falciparum in the Brazilian Amazonas to the combination of sulfadoxine and pyrimethamine]. Alecrim M das G; Alecrim WD; de Albuquerque BC; Dourado HV; Wanssa Mdo C Rev Inst Med Trop Sao Paulo; 1982; 24(6 Suppl):44-7. PubMed ID: 6764287 [No Abstract] [Full Text] [Related]